American College of Clinical Pharmacy
      Search      Cart
         

Pulmonary PRN Focus Session -- Updates in Pulmonary Hypertension Management Across the Continuum of Care

Tuesday, October 29, 2019 from 3:00 PM to 4:30 PM EST at 2nd Floor: Nassau

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-19-196-L01-P
Activity Type: An Application-Based Activity


Speakers
  • Moderator: Kristen T. Pogue, Pharm.D., BCPS-AQ Cardiology
    Clinical Pharmacist, Cardiology, University of Michigan Health System, Ann Arbor, Michigan
      View Biography

Updates from the 6th World Symposium on Pulmonary Hypertension
3:00 PM

Speakers
  • James  Coons, Pharm.D., BCPSSpeaker: James Coons, Pharm.D., BCPS
    Associate Professor, Department of Pharmacy and Therapeutics University of Pittsburgh School of Pharmacy Clinical Pharmacist, Cardiology UPMC Presbyterian Hospital
      View Biography


Learning Objectives
1. Describe the updated definition for the diagnosis of pulmonary arterial hypertension (PAH) and its implications on pharmacologic treatment.
2. Select appropriate therapeutic goals and identify an appropriate timeline to evaluate a patient’s response to pharmacologic treatment of PAH.
3. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.
Unique Challenges in the Management of Pulmonary Hypertension in the Ambulatory Setting
3:30 PM

Speakers
  • Rebekah H. Anguiano, Pharm.D., BCPS, BCACPSpeaker: Rebekah H. Anguiano, Pharm.D., BCPS, BCACP
    Clinical Assistant Professor, Pharmacy Practice; Clinical Pharmacist, Ambulatory Pharmacy Services, University of Illinois at Chicago, Chicago, Illinois


Learning Objectives
1. Identify barriers to treatment with PAH-targeted therapies in the ambulatory setting and available options to address and overcome these barriers.
2. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.
3. Compose a pharmacotherapy regimen for a patient with PAH in the ambulatory setting.
4. Identify strategies to address barriers associated with continuation of PAH-targeted therapies in patients transitioning between the ambulatory and acute care settings.
Unique Challenges in the Management of Pulmonary Hypertension in the Critical Care Setting
4:00 PM

Speakers
  • Amy L. Dzierba, Pharm.D., FCCM, BCPS, BCCCPSpeaker: Amy L. Dzierba, Pharm.D., FCCM, BCPS, BCCCP
    Clinical Specialist, Critical Care Program Director, Critical Care Residency Department of Pharmacy, New York Presbyterian Hospital, New York, New York
      View Biography


Learning Objectives
1. Evaluate patient-specific risk factors used to quantify disease severity and guide initial pharmacotherapy in patients diagnosed with PAH.
2. Identify strategies to address barriers associated with continuation of PAH-targeted therapies in patients transitioning between the ambulatory and acute care settings.
3. Recognize barriers to initiation of PAH-targeted therapies in the acute care setting.